Highest dose, obesity trial obesity-plus-diabetes trial (treatment-policy estimand): Semaglutide: 14.9% (STEP 1) 9.6% (STEP 2), a 5.3 point gap Tirzepatide: 20.9% (SURMOUNT-1) 14.7% (SURMOUNT-2), a 6.2 point gap Retatrutide: 25.0% (TRIUMPH-1) 20.8% (TRIUMPH-2 only efficacy-estimand currently reported so true gap is larger) It's still unclear the reason why we observe less weight loss in those with T2D
At 4mg, meal timing becomes important
For HRV, the pattern differs
Step 1: Consultation Before treatment, youll meet with a healthcare provider to discuss your symptoms, lifestyle, and goals
difficile can release toxin A and toxin B (Popoff, 2018), which induce the production of pro-inflammatory cytokines and inflammatory mediators in a variety of cell lines (Zhang and Feng, 2016)